Psilocybin
ATMA Welcomes Dr. Scott Shannon, MAPS MDMA Phase 3 Principal Investigator, to Expand Its’ Clinical Training Expertise in MDMA-Assisted Therapy
CALGARY, October 24, 2023 – ATMA Journey Centers Inc. (“ATMA”), a Canadian company with a primary focus on advancing psychedelic-assisted therapy,…
-
Psychedelics1 week ago
MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
-
Psychedelics1 week ago
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
-
Psychedelics1 week ago
Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings
-
Psychedelics1 week ago
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
-
Psilocybin6 days ago
The Psychedelic Scene in Oaxaca, Mexico
-
Psychedelics1 week ago
MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
-
Ketamine1 week ago
What marijuana reclassification could mean for health treatments
-
Psychedelics1 week ago
Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings